Biogen Inc

Biogen Inc.’s decade‑long stock swings reveal biotech’s volatile mix of R&D, pricing pressure and supply‑chain risk—insights for investors, clinicians and policy makers.

Biogen’s hidden strengths emerge from mRNA, digital‑therapeutics, and a solid pipeline, but patent cliffs and pricing pressure threaten its 2025 growth targets.

Biogen’s CEO buys 1,342 shares, plus a 3‑year RSU, showing exec confidence and aligning long‑term incentives with shareholder value.

Biogen’s $5.6 billion purchase of Apellis adds approved drugs Syfovre and Empaveli, expanding its rare disease and immunology portfolio with proven efficacy and a strong growth outlook.

Biogen’s litifilimab shows significant Phase‑2 success in cutaneous lupus, offering a targeted IFN‑α blocker that could reshape autoimmune therapy.

Biogen’s litifilimab shows breakthrough Phase‑2 success in cutaneous lupus erythematosus, promising new high‑margin treatment and a strategic shift away from Alzheimer’s research.

Biogen’s latest update reveals promising Phase 1b results for salanersen in spinal muscular atrophy, outlining a Phase 3 plan to evaluate safety, efficacy, and combination therapy while navigating accelerated regulatory pathways.

Biogen’s latest data on higher‑dose nusinersen, salanersen, and zorevunersen show promise for spinal muscular atrophy and Dravet syndrome, highlighting progress in precision antisense therapies for rare neurological diseases.

Biogen’s Q4 2025 earnings reveal cost‑cutting tactics amid patent cliffs, a shift toward Alzheimer’s and rare‑disease drugs, and a focus on patient‑centric market access strategies.

Biogen’s Q4 2025 earnings show a 5% sales dip from its MS line but strong cost cuts and new Alzheimer’s/rare‑disease revenue, positioning 2026 earnings above forecasts.